When planning infrastructure spending on broadband deployment, rules should be technology and vendor neutral.
Price Controls Are Still Bad Medicine
Price controls on pharmaceuticals distort the medical marketplace and will not lower drug prices.
Only Taxpayers Know What They Owe and the IRS Should Never File Anyone’s Taxes
Sen. Warren’s proposal would vastly expand the size and scope of the IRS’s power.
The Senate Must Reject Price Controls on Pharmaceuticals
Senators should reject price controls on pharmaceuticals; they will not lower prices and lead to fewer future cures.
The Senate Should Not Implement Price Controls on Pharmaceuticals
Price controls on pharmaceuticals will not lower prices and will lead to fewer future cures.
Limiting Access to Tobacco Harm Reduction Products Harms Public Health
The FDA’s decision to stop Juul from selling e-cigarette products in the U.S. will harm public health.
GAO Report Reveals Significant Duplication and Overlap in Broadband Programs
A recent report from the Government Accountability Office lays out paths to reduce wasteful practices in broadband programs.
Regulating PBMs Will Not Lower Drug Costs
Increasing regulations on pharmacy benefit managers will not reduce the cost of pharmaceuticals.
Congress Must Make the Right Decisions on Consumer Data Privacy
The failure to pass a national framework for data privacy has left a void that is being filled by the states.
The Convoluted Saga of Maryland’s Purple Line Continues
Since its inception, the Purple Line has been beset by mismanagement, corruption, and delays.